Enhanced H. pylori Treatment Using a β ‐Cyclodextrin–Propolis Complex: A Randomized Clinical Trial
BioMed Research International · 2026-01 · 2026 (1)
DOI: 10.1155/bmri/6257147 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift BioMed Research International, online erschienen am 07.07.2026. Verfasst von Aisa Mehri und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran, umsha.ac.ir. Hauptthemen laut MEDLINE: beta-Cyclodextrins, Helicobacter pylori, Helicobacter Infections, Propolis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hamadan University of Medical Sciences.
Abstract (Originalsprache)
Background
Helicobacter pylori infection poses a significant global health burden, with rising antibiotic resistance and treatment‐related side effects highlighting the need for adjunctive therapies. Propolis, a natural resin with known antimicrobial and anti‐inflammatory properties, suffers from poor solubility and bioavailability. This study evaluated a β ‐cyclodextrin–propolis complex designed to enhance delivery and therapeutic efficacy in H. pylori ‐infected patients. Materials and Methods In a double‐blind, randomized clinical trial at Hamadan University of Medical Sciences, biopsy‐confirmed H. pylori patients received standard quadruple therapy plus omeprazole. The treatment group ( n = 28) also received 250 mg/day of the β ‐cyclodextrin–propolis complex for 2 months; the control group ( n = 12) received placebo capsules. Outcomes were assessed using fecal antigen tests and gastrointestinal symptom questionnaires 2 months posttreatment. Characterization of the complex was performed using FESEM, FTIR, and drug release profiling in PBS (pH 7.4).
Results
The complex demonstrated a successful formation and a sustained propolis release profile. Clinically, 57.1% of treated patients achieved negative antigen tests and symptom resolution, compared with 41.6% in the control group. Adverse effects were mild and comparable between groups.
Conclusion
These findings suggest that the β ‐cyclodextrin–propolis complex may serve as an effective natural adjunct to standard H. pylori treatment, offering potential benefits in eradication rates and symptom relief. Trial Registration Iranian Registry of Clinical Trials (IRCT): 20230503058065N1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran, umsha.ac.ir.
- Department of Gastroenterology and Hepatology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran, umsha.ac.ir.
- Clinical Research Development Unit of Shahid Beheshti Hospital, Hamadan University of Medical Sciences, Hamadan, Iran, umsha.ac.ir.
- Social Determinants of Health Research Center, Institute of Health Sciences and Technologies, Hamadan University of Medical Sciences, Hamadan, Iran, umsha.ac.ir.
ORCID-Profile: Shabnam Pourmoslemi
Förderung
- Hamadan University of Medical Sciences
Zitieren
APA
Mehri, A., Pourmoslemi, S., Khalilian, A., Safari, M., & Ayubi, E. (2026). Enhanced H. pylori Treatment Using a β ‐Cyclodextrin–Propolis Complex: A Randomized Clinical Trial. BioMed Research International, 2026(1). https://doi.org/10.1155/bmri/6257147
Vancouver
Mehri A, Pourmoslemi S, Khalilian A, Safari M, Ayubi E. Enhanced H. pylori Treatment Using a β ‐Cyclodextrin–Propolis Complex: A Randomized Clinical Trial. BioMed Research International. 2026;2026(1). doi:10.1155/bmri/6257147
BibTeX
@article{Mehri2026,
author = {Mehri, Aisa and Pourmoslemi, Shabnam and Khalilian, Alireza and Safari, Mahdi and Ayubi, Erfan},
title = {Enhanced H. pylori Treatment Using a β ‐Cyclodextrin–Propolis Complex: A Randomized Clinical Trial},
journal = {BioMed Research International},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/bmri/6257147}
}
EUVIMED